Yu Ying, Tu Li, Liu Yang, Song Xueyi, Shao Qianqian, Tang Xiaolong
School of Medicine, Anhui University of Science and Technology, Huainan 232001, China.
First Affiliated Hospital, Anhui University of Science and Technology, Huainan 232001, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2025 Jul 20;45(7):1397-1408. doi: 10.12122/j.issn.1673-4254.2025.07.06.
To investigate the mechanism by which transforming growth factor‑β (TGF‑β) regulates major histocompatibility complex class I (MHC-I) expression in hepatocellular carcinoma (HCC) cells and its role in immune evasion of HCC.
HCC cells treated with TGF‑β alone or in combination with SB-431542 (a TGF-β type I receptor inhibitor) were examined for changes in MHC-I expression using RT-qPCR and Western blotting. A RNA interference experiment was used to explore the role of miR-23a-3p/IRF1 signaling in TGF‑β‑mediated regulation of MHC-I. HCC cells with different treatments were co-cultured with human peripheral blood mononuclear cells (PBMCs), and the changes in HCC cell proliferation was assessed using CCK-8 and colony formation assays. T-cell cytotoxicity in the co-culture systems was assessed with lactate dehydrogenase (LDH) release and JC-1 mitochondrial membrane potential assays, and T-cell activation was evaluated by flow cytometric analysis of CD69 cells and ELISA for TNF-α secretion.
TGF‑β treatment significantly suppressed MHC-I expression in HCC cells and reduced T-cell activation, leading to increased tumor cell proliferation and decreased HCC cell death in the co-culture systems. Mechanistically, TGF-β upregulated miR-23a-3p, which directly targeted IRF1 to inhibit MHC-I transcription. Overexpression of miR-23a-3p phenocopied TGF‑β‑induced suppression of IRF1 and MHC-I.
We reveal a novel immune escape mechanism of HCC, in which TGF‑β attenuates T cell-mediated antitumor immunity by suppressing MHC-I expression through the miR-23a-3p/IRF1 signaling axis.
探讨转化生长因子-β(TGF-β)调节肝细胞癌(HCC)细胞中主要组织相容性复合体I类(MHC-I)表达的机制及其在HCC免疫逃逸中的作用。
使用逆转录定量聚合酶链反应(RT-qPCR)和蛋白质免疫印迹法检测单独用TGF-β或与SB-431542(一种TGF-βI型受体抑制剂)联合处理的HCC细胞中MHC-I表达的变化。采用RNA干扰实验探讨miR-23a-3p/干扰素调节因子1(IRF1)信号通路在TGF-β介导的MHC-I调节中的作用。将不同处理的HCC细胞与人外周血单个核细胞(PBMC)共培养,使用细胞计数试剂盒-8(CCK-8)和集落形成试验评估HCC细胞增殖的变化。通过乳酸脱氢酶(LDH)释放和JC-1线粒体膜电位试验评估共培养系统中的T细胞毒性,并通过对CD69细胞的流式细胞术分析和检测肿瘤坏死因子-α(TNF-α)分泌的酶联免疫吸附测定(ELISA)评估T细胞活化。
TGF-β处理显著抑制HCC细胞中MHC-I的表达并降低T细胞活化,导致共培养系统中肿瘤细胞增殖增加和HCC细胞死亡减少。机制上,TGF-β上调miR-23a-3p,其直接靶向IRF1以抑制MHC-I转录。miR-23a-3p的过表达模拟了TGF-β诱导的对IRF1和MHC-I的抑制作用。
我们揭示了一种新的HCC免疫逃逸机制,其中TGF-β通过miR-23a-3p/IRF1信号轴抑制MHC-I表达,从而减弱T细胞介导的抗肿瘤免疫。